US 12,226,446 B2
WS-635 uses thereof in medicine
Faming Zhang, Hubei (CN); Jian Cui, Hubei (CN); Yao Yu, Hubei (CN); Minglong Hu, Hubei (CN); and Zhongcong Xie, Andover, MA (US)
Assigned to WATERSTONE PHARMACEUTICALS(WUHAN) CO., LTD., Hubei (CN); and THE GENERAL HOSPITAL CORPORATION, Boston, MA (US)
Appl. No. 17/429,667
Filed by WATERSTONE PHARMACEUTICALS(WUHAN) CO., LTD., Hubei (CN); and THE GENERAL HOSPITAL CORPORATION, Boston, MA (US)
PCT Filed Oct. 11, 2019, PCT No. PCT/CN2019/110576
§ 371(c)(1), (2) Date Aug. 10, 2021,
PCT Pub. No. WO2021/068188, PCT Pub. Date Apr. 15, 2021.
Prior Publication US 2022/0105149 A1, Apr. 7, 2022
Int. Cl. A61K 38/13 (2006.01); A61P 25/00 (2006.01)
CPC A61K 38/13 (2013.01) [A61P 25/00 (2018.01)] 17 Claims
 
1. A method of treating, preventing, or lessening postoperative cognitive dysfunction (POCD) in a subject in need thereof, the method comprising the step of administering to the subject a therapeutically effective amount of a compound of Formula I or a stereoisomer, a tautomer, an N-oxide, a solvate, a pharmaceutically acceptable salt or a prodrug thereof,

OG Complex Work Unit Chemistry